ABSTRACT
INTRODUCTION
Lung cancer is the most common cause of cancer related deaths and its main primary types are small lung cancer (10~15%) and non-small lung cancer (85~90%) worldwide [1, 2] . In general, the treatment for lung cancer is surgery, chemotherapy, radiotherapy, immunotherapy and targeted therapy mainly for EGFR, VEGF, ALK and NF-κB [3, 4] .
It is well documented that arsenic trioxide (As 2 O 3 ) exerts antitumor effect in several cancers including leukemia [5] , breast cancer [6] , prostate cancer [7] , lung cancer [8] , cervical cancer [9] , gastric cancer [10, 11] , pancreatic cancer [12] , hepatocellular cancer [13] and glioblastoma [14] . Thus, Trisenox as a trade name of arsenic trioxide from Cephalon Biopharmaceutical Company has been applied to treat acute promyelocytic leukemia (APL) as a chemotherapeutic agent approved by the US FDA [15] . Recently tetraarsenic hexoxide(As 4 O 6 ) showed antitumor effect more effectively than arsenic trioxide in HPV 16-positive SiHa cervical cancer [16] and enhanced radiation sensitivity to reduce the growth of Meth-A induced fibrosarcoma and nasopharyngeal squamous cancer implanted in Balb/c nu/nu mice [17] . Nevertheless, new combination therapy has been attractive with low dose of arsenic trioxide and natural compounds such as naringenin [18] , resveratrol [19] , retinoic acid [20] and lipoic acid [21] , since the toxicity and poisoning of arsenic trioxide were reported as cardiac toxicity [22, 23] , reproductive toxicity [24] , hepatotoxicity [25] and resistance [26, 27] . As known as anticancer herbal medicines, Oldenlandia diffusa is known to have anticancer [28] , antioxidant [29] , anti-inflammatory [30] and immunomodulatory [31] and also Salvia miltiorrhiza has Research Paper www.impactjournals.com/oncotarget anti-inflammatory [32] , antioxidant [33] and anti-cancer activity [34] with constituents of diterpene quinone, tanshinoneI, tanshinone II cryptotanshinone, and miltirone [35] .
Thus, in the same line, the aim of the present study is to elucidate antitumor mechanism of PROS, an arsenic herbal mixture of tetraarsenic hexoxide (PR) and ethanol extract of Oldenlandia diffusa and Salvia miltiorrhiza (OS) in association with angiogenesis and apoptosis in non-small cell lung cancer cells (NSCLCs), since PR showed resistant cytotoxicity in A549 and H460 NSCLCs compared to other cancers such as HCT-116 colon cancer, 786-O renal cancer, PC-3 and DU145 prostate cancers.
RESULTS

PROS exerted significant cytotoxicity in A549 and H460 NSCLCs better than PR or OS alone
Though PR or tetraarsenic hexoxide (As 4 O 6 ) showed cytotoxic effect in several cancers such as SW620 colon cancer [36, 37] , CaSki cervical cancer [16] , U87MG malignant glioma cells [38] , U937 leukemia [39] with IC 50 of ~ 0.4 µg/ml (1 µM) , PR exhibited weak cytotoxicity in A549 and H460 NSCLCs with IC 50 of over 4 µg/ml (10 µM), respectively, while OS did not show any toxicity up to 360 µg/ml ( Figure 1A ). However, OS initiated synergistic cytotoxicity with 2.5 µg/ml (6.3 µM) PR in A549 and H460 NSCLCs from 180 µg /ml ( Figure 1A ). In contrast, PROS, combination of 2.5µg/ml PR and 180 µg/ ml OS, exerted significant cytotoxicity in A549 and H460 NSCLCs, HCT-116 colon cancer, 786-O renal cancer, PC-3 and DU145 prostate cancers compared to PR alone ( Figure 1B and 1D ), but not in YD-8 oral squamous cells ( Figure 1B ). To test expression of p-STAT3 (Tyr705) and total-STAT3 in HCT-116, 786-O, PC3, Du145, A549, H460 and YD-8 cells, Western blotting was performed using an anti-STAT3 (Tyr705) and total-STAT3 antibodies. As shown in Figure 1C , p-STAT3 was highly expressed in HCT-116, 786-O, PC3, Du145, A549 and H460, while that was low expressed in YD-8 cell lines ( Figure 1C) . Likewise, apoptotic morphology was shown only in PROS treated cells compared to OS or PR alone treated control cells ( Figure 1E ).
PROS induced sub G1 accumulation, S phase arrest, attenuated the expression of pro-PARP, Bcl-2, p-ERK, cyclin E, cyclin A, Cdk-2 and E2F1 in A549 or/and H460 cells
To confirm the apoptotic effect of PROS, cell cycle analysis and DAPI staining were conducted in A549 cells treated by PROS compared to PR or OS alone. PROS increased sub-G1 population, induced S phase arrest to 29.45% compared to PR (8.75%) or OS (8.21%) ( Figure 2A ) and increased apoptotic bodies compared to PR or OS alone in A549 and H460 cells ( Figure 2B) . Likewise, PROS attenuated the expression of pro-PARP, Bcl-2, p-ERK ( Figure 2C ), cleaved PARP and also suppressed the expression of Cyclin E, Cyclin A, CDK2 and E2F1 as cell cycle related genes in A549 and H460 cells ( Figure 2D ).
PROS suppressed the expression of p-STAT3, p-ERK, p-Src, p-AKT, COX-2, SOCS-1 and disrupted the binding of STAT3 with CDK2 or VEGF in NSCLCs PROS reduced phosphorylation of signal transducer and activator of transcription 3 (STAT3) (Tyr705) as a transcription factor in A549 and H460 cells ( Figure 3A) and also attenuated the phosphorylation of interleukin 6 (IL-6) activated ERK and STAT3 in STAT3 low level H1299 cells ( Figure 3C ). Likewise, PROS reduced the cell viability of IL-6-stimulated H1299 cells ( Figure 3B ). Consistently, PROS reduced the expression of p-Src, p-AKT, cyclooxygenase 2 (COX-2) as survival genes and suppressor of cytokine signaling 1 (SOCS-1) that promotes tumor progression and toll like receptor (TLR) signaling [40] , but not SHP-1, in A549 and H460 cells ( Figure 3D ). Additionally, IP revealed that PROS attenuated the expression of VEGF and CDK2 and also disrupted the binding of STAT3 with CDK2 or VEGF after the treatment with PROS for 24 h in A549 and H460 cells ( Figure 3E ), while the score of protein-protein interaction (PPI) between STAT3 and CDK2, STAT3 and VEGF or VEGF and CDK2 were 0.624, 0.945 and 0.443, respectively.
PROS inhibited angiogenesis via inhibition of p-VEGFR2/p-SRC/p-STAT3 axis signaling
PROS inhibited VEGF induced proliferation, migration and tube formation in HUVECs at nontoxic concentration ( Figure 4A-4C) . Consistently, PROS suppressed neovascularization in CAM assay ( Figure 4D ). Furthermore, PROS reduced phosphorylation of VEGFR2, Src and STAT3 in VEGF treated HUVECs ( Figure 4E ). Consistently, PROS suppressed the migratory activity in A549 cells compared to PR or OS alone along with reduced expression of VEGF ( Figure 4F and 4G) .
PROS abrogated the growth of H460 cells implanted in BALB/c athymic nude mice via inhibition of STAT3 and VEGF and activation of caspase 3
To confirm in vitro antiangiogenic and apoptotic effect of PROS, animal study was conducted in H460 xenograft model. PROS did not affect body weight of mice ( Figure 5A ) and significantly reduced the tumor volumes ( Figure 5B ) and weights ( Figure 5C ) compared www.impactjournals.com/oncotarget to untreated control. Furthermore, immunohistochemistry revealed that the expression of p-STAT3 and VEGF was suppressed and cleaved caspase 3 was activated in tumor sections isolated from PROS treated group mice compared to untreated control ( Figure 5D ).
DISCUSSION
Emerging evidences revealed that arsenic compounds such as asrsenic trioxide (As 2 O 3 ) [6, 15] , tetraarsenic hexoxide (As 4 O 6 or PR) [38, 39] and 4 cells/well and treated with PROS for 24 h. Then the cell viability was assessed by MTT assay. Serum-starved HUVECs were plated onto 96-well microplate at a density of 1 × 10 3 cells/well and exposed to PROS in M199 containing 5% heat-inactivated FBS, heparin (5 unit/ml) and VEGF 10 ng/ml for 48 h, and the proliferation was assessed by MTT assay. Data represent means ± SD. ** p < 0.01 and *** P < 0.001 vs vehicle treated control. www.impactjournals.com/oncotarget tetraarsenic tetrasulfide (As 4 S 4 ) [41, 42] have antitumor effects in several cancers including acute promyelocytic leukemia (APL). Currently Trisenox (asrsenic trioxide injection) from Cephalon Pharmaceutical Company has been commercially used for APL treatment [43, 44] , though it shows complication indications such as APL differentiation syndrome [45] , cardiac conduction abnormalities [46] and hepatotoxicity [47] . Recently combination therapy of arsenic trioxide and natural compounds such as cucurbitacine B [48] , cryptotanshinone [49] , naringenin [18] , resveratrol [19] , retinoic acid [20] and lipoic acid [21] is recommended for synergistic antitumor effect for reducing adverse effect of arsenic compounds [50] . Here the antitumor mechanism of PROS, an arsenic herbal mixture that has been used for several cancers at KMD clinics, was explored in NSCLCs. PROS exerted significant cytotoxicity in several cancers such as A549, H460, HCT-116, 786-O, PC-3 and DU145 cancers compared to OS or PR alone, while PR showed weaker cytotoxicity in A549 and H460 NSCLCs compared to other cancers. Also, PROS induced sub G1 accumulation, S phase arrest, increased apoptotic bodies, and attenuated the expression of pro-PARP in A549 and H460 cells, indicating the apoptotic effect and S phase arrest of PROS. Consistently, PROS suppressed the expression of cell cycle related proteins such as Cyclin E, Cyclin A, CDK2, E2F1 in A549 and H460 cells, since Cyclin E binds to CDK2, which is required for the transition from G1 to S phase, Cyclin A can regulate cell cycle through S and G2/M phases with CDK2 or CDK1 [51] and also E2F1 is working during the G1/S transition. Also, as antiapoptotic proteins, the expression of Bcl-2, p-Src, p-ERK, p-AKT, COX-2 and SOCS-1 was attenuated in PROS treated A549 and H460 cells, implying PROS inhibits antiapoptotic proteins, leading to apoptosis.
It is well documented that STAT3 is phosphorylated for tumor progression and inflammation by receptorassociated Janus kinases (JAK) [52, 53] . Interestingly, PROS attenuated phosphorylation of STAT3 in A549 and H460 cells and also reduced the expression of IL6 Accumulating evidences reveal that targeting angiogenesis is a good strategy for effective anticancer therapy [54, 55] . Also, STAT3 is closely associated with VEGF [56, 57] or CDK2 [58] In summary, PROS showed significant cytotoxicity, sub G1 accumulation and S phase arrest, via inhibition of pro-PARP, Bcl-2, Cyclin E, Cyclin A, CDK2, E2F1, p-Src, p-STAT3, p-ERK, p-AKT, COX-2 and SOCS-1 along with disrupted binding of STAT3 with CDK2 or VEGF in NSCLCs. Furthermore, PROS inhibited VEGF induced proliferation, migration and tube formation in HUVECs and ex vivo angiogenesis in CAM via reduced phosphorylation of VEGFR2, Src and STAT3. Also, PROS reduced the growth of H460 cells in nude mice via inhibition of STAT3, and VEGF and activation of caspase 3. Overall, these findings demonstrate that PROS exerts antiangiogenic and apoptotic effects via inhibition of STAT3/VEGF/CDK2 axis signaling as a potent anticancer agent for lung cancer treatment ( Figure 6 ).
MATERIALS AND METHODS
Preparation of PROS
Tetraarsenic hexoxide (As 4 O 6, MW = 395.6828;PR) from processed Realgar was provided from Chonjisan Networks. Oldenlandia diffusa (25 g ) and Salvia miltiorrhiza (10g) were extracted with 50% EtOH for 3 days at room temperature, concentrated using a rotary evaporator (Eyela, Tokyo, Japan) and freeze-dried to obtain 4.64 g (yield = 13.25%) of ethanol extracts of Oldenlandia diffusa and Salvia miltiorrhiza (OS). PROS consists of 2.5 µg/ml tetraarsenic hexoxide (PR) and OS herbal mixture (180 µg/ml). streptomycin. Human umbilical vein endothelial cells (HUVECs) were isolated from fresh human umbilical cord vein by collagenase treatment. The cells were cultured in M199 supplemented with 20% heat inactivated FBS, 3 ng/ ml bFGF, 5 units/ml heparin and 100 units/ml antibioticantimycotic on 0.1% gelatin-coated flasks at 37°C in a humidified atmosphere containing 5% CO 2 . HUVECs were used within passages three to six.
Cell culture
Cytotoxicity assay
The cytotoxicity of PR, OS and PROS was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, A549 and H460 cells (1 × 10 4 cells/well) were seeded onto 96-well culture plate and exposed to various concentrations of PR or/and OS (180 µg/ml) for 24 h, while HUVECs were exposed only to PROS for 24 h. The cells were incubated with MTT (1 mg/mL) (Sigma Chemical) for 2 h and then treated with MTT lysis solution overnight. Optical density (OD) was measured using a microplate reader (Molecular Devices Co., USA) at 570 nm. Cell viability was calculated as a percentage of viable cells in drug treated groups versus untreated control.
Cell cycle analysis
A549 cells (1 × 10
6 cells/ml) were treated with PR (2.5 µg/ml) or/and OS (180 µg/ml) for 24 h, washed twice with cold PBS and fixed in 75% ethanol at −20°C. The cells were incubated with RNase A (10 mg/ml) for 1 h at 37°C and stained with propidium iodide (50 μg/ml) for 30 min at room temperature in dark. The stained cells were analyzed for the DNA content by FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA) using Cell Quest Software.
DAPI staining and microscopic observation
A549 and H460 cells were treated with PR (2.5 µg/ ml) or/and OS (180 µg/ml) for 24 h and the treated cells were seeded onto poly-L-lysine coated slides and fixed using 4% methanol-free formaldehyde solution for 25 min at 4°C. After washing the slides with PBS, mounting medium with DAPI was dispersed over the entire section of slides and visualized under AxioVision 4.0 fluorescence microscope (Carl Zeiss Inc., Weimar, Germany).
VEGF induced proliferation assay
HUVECs (1 × 10 4 cells) were seeded onto 0.1% gelatin-coated 96-well microplates and incubated in a humidified incubator for 24 h. the cells were cultured in M199 containing 5% heat-inactivated FBS, 10 ng/ml VEGF the presence or absence of PROS for 48 h and the viability of HUVECs was determined by using MTT assay. www.impactjournals.com/oncotarget
VEGF induced migration assay
Confluent HUVECs (3 × 10 5 cells) were seeded onto 0.1% gelatin coated 6-well plates and the monolayer was wounded by using a tip of a 200ml pipette tip. Then cells were treated with PROS in M199 with 5% FBS, 10 ng/ ml VEGF and 5 units/ml heparin for 18 h. Then the cell were rinsed with PBS and stained with Diff Quick solution and randomly chosen fields were photographed under a light microscope at X100 magnification. The number of migrated cells was counted.
Wound healing assay
The motility of A549 cells was assayed by a woundhealing assay. Cells (4 × 10 5 cells/mL) were seeded onto 6-well plate and incubated at 37°C. The confluent cells were scratched with a 200 μL pipet tip, followed by washing with PBS, and then treated with PR (2.5 µg/ ml) or/and OS (180 µg/ml) in a complete medium for 16 h. Then the cells were fixed and stained with DiffQuick, and randomly chosen fields were photographed under a fluorescence microscope (AXIO observer A1, Zeiss, Germany). The number of cells migrated into the scratched area was calculated.
VEGF induced tube formation assay
In vitro differentiation of HUVECs into capillarylike tubes was evaluated on Matrigel. HUVECs (2 × 10 4 cells) were seeded onto Matrigel-coated 24-well plates, and were cultured in M199 with 1% FBS, 10 ng/ml VEGF and 5 units/ml heparin with or without PROS for 18 h. Then, cells were fixed with 4% paraformaldehyde, and randomly chosen fields were photographed under an Axiovert S 100 light microscope (Carl Zeiss, Thornwood, NY, U.S.A.) at ×100 magnification.
Chorioallantoic membrane assay
The ex vivo angiogenic activity was assessed using chorioallantoic membrane (CAM) assay. PROS and VEGF (100 ng) were loaded onto 1/4 piece of thermonox disk (Nunc, Naperville, IL, USA). The dried thermonox disk was applied to the CAM of a 10-day-old embryo. After 2 days incubation, a fat emulsion was injected under the CAM for better visualization of the blood vessels. The number of newly formed blood vessels was counted.
Immunoprecipitation
A549 and H460 cells were lyzed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM NaF, 1 mM EDTA, 1mM Na 3 VO 4 , and 1× protease inhibitor cocktail), and then were immuneprecipitated with STAT3, CDK2 and VEGF antibodies. Thereafter, Protein A/G sepharose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were applied. The final precipitated proteins were subjected to immunoblotting with the indicated antibodies.
Western blotting
A549 and H460 cells (1 × 10 6 cells/ml) were treated with PROS for 24 h, lyzed in lysis (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF, and 1× protease inhibitor cocktail) on ice, and spun down at 14,000×g for 20 min at 4°C. The supernatants were collected and quantified for protein concentration by using RC DC protein assay ki (Bio-Rad, Hercules, CA, USA). The protein samples were separated on 4-12% NuPAGE BisTris gels (Novex, Carlsbad, CA, USA) and transferred to a Hybond ECL transfer membrane for detection with antibodies for PARP, cleaved-PARP, Caspase3, Bcl-2, p53, p21, cyclin E, Cyclin A, CDK2, E2F-1, p-VEGFR2, VEGFR2, phospho-Src, phospho-AKT, cyclinD1, phospho-JNK, JNK, phospho-p38 MAPK, p38 MAPK, phospho-ERK, ERK, phospho-STAT3, STAT3 and SHP-1 (Cell signaling Technology, Beverly, MA), SOCS-1, COX-2 and VEGF (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), and β-actin (Sigma, St. Louis, MO, USA).
H460 xenograft model
The animal studies were conducted under guidelines approved by Institutional Animal Care and use Committee, Kyung Hee University [KHUASP(SE)-17-003]. Briefly, 2 million H460 cells were mixed with Matrigel (50%, in 100 μl; Becton Dickinson, Bedford, MA, USA) and injected subcutaneously on the right flank of 6-week-old female BALB/c athymic nude mice (NARA Biotech, Seoul, Korea). One day after tumor inoculation, mice were daily given oral administration of PROS (PR 125 µg/kg + OS 20 mg/kg) for 18 days. Tumor volumes were measured every six days with a caliper, and calculated. According to the formula [(L × W 2 )/2], where L and W stand for length and width, respectively. All mice were sacrificed 18 days after tumor inoculation and the tumors were excised and weighed.
Immunohistochemistry
Tumors were fixed in 10% neutral buffered formalin for 16 h, embedded in paraffin, and sectioned to 4 µm thickness. The tumor sections were immobilized and deparaffinized by immersing in xylene, dehydrated in a graded series of ethanol and washed with distilled water. For antigen retrieval, the tumor sections were boiled in 10 mM sodium citrate buffer (pH 6.0) for 10 min and cooled at room temperature. After washing with Tris-buffered saline (TBS), endogenous peroxidase activity was blocked by incubation in 3% H 2 O 2 -methanol for 10 min at room temperature. The sections were stained with antibodies for p-STAT3 (Cell Signaling Technology, Beverly, MA, USA), cleaved-caspase-3 (Cell Signaling Technology, Beverly, MA, USA) and VEGF (Santa Cruz Biotechnologies, Santa Cruz, CA, USA ) over-night at 4°C using ABC and DAB kits (Vector Lab., Inc., Burlingame, CA, USA) and also counterstained with Mayer's hematoxylin solution (Sigma chemical Co., St. Louis, MO, USA). All stained sections were photographed under an Axiovert S 100 light microscope (Carl Zeiss, Inc., USA) at X200 magnifications.
Statistical analysis
The results were expressed as the means ± SD from at least three independent experiments. Statistical analyses were conducted by Student's t-test using Graphpad Prism 5.0 software (GraphPad Software, San Diego, CA, USA). P value < 0.05 was considered statistically significant.
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